[email protected] These authors have contributed equally to this work This article was submitted to Microbiotechnology, a section of the journal Frontiers in Microbiology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
This precision in dosing is essential for achieving reproducible results and conducting reliable studies into the benefits and side effects of peptide research
Phase 2 obesity data showed clear separation by 24 weeks: the 12 mg group averaged 17.5% body-weight reduction at week 24 and 24.2% at week 48
The clinic advises starting with a low dose and gradually increasing it to minimize gastrointestinal discomfort
The covariates were adjusted in the PSM model for a priori-identified potential confounders, such as age, sex, race/ethnicity, nicotine dependence, BMI, type 2 diabetes, hypertension, hyperlipidaemia, hypercholesterolaemia, chronic respiratory disease, chronic renal diseases, BP, chronic kidney disease, peripheral vascular diseases, diabetes-related microvascular complications, glomerular diseases, cirrhosis of the liver, osteoporosis, sleep apnoea, abnormal laboratory findings (HbA 1c , serum cholesterol, LDL-cholesterol, HDL-cholesterol and triacylglycerol [TG]) and intake of cardiovascular medications (Table 1)